The unique reproductive concerns of young women with breast cancer

Advances in Experimental Medicine and Biology

Volumn 732, Issue , 2012, Pages 77-87

  Ruddy, Kathryn J ^a   Partridge, Ann H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; NAVELBINE; PACLITAXEL;

AMENORRHEA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CRYOPRESERVATION; DRUG SAFETY; EMBRYO TRANSFER; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; HUMAN; ONSET AGE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARIAN RESERVE; PATIENT COUNSELING; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS; REPRODUCTIVE HEALTH; REPRODUCTIVE PROCEDURES; REPRODUCTIVE SUCCESS; REPRODUCTIVE TOXICITY; SEXUAL HEALTH; WOMEN'S HEALTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; NEOPLASM RECURRENCE, LOCAL; PREGNANCY;

EID: 84856275114     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-2492-1_6     Document Type: Article

References (75)

1. Oktay K., et al. (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240-244
2. Adams E., et al. (2011) The experiences, needs and concerns of younger women with breast cancer: a meta-ethnography. Psychooncology 20(8):851-861
3. Hickey M, et al (2009) Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 15(3):323-339
4. Partridge AH., et al. (2004)Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174-4183 (Pubitemid 41185188)
5. Ruddy K., et al. (2011) Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors. Menopause 18:105-108
6. Dow KH (1994) Having children after breast cancer. Cancer Pract 2(6):407-413
7. Thewes B., et al. (2005) Fertility-and menopauserelated information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 23(22):5155-5165 (Pubitemid 46224024)
8. Duffy CM, Allen SM, Clark MA (2005) Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 23(4):766-773 (Pubitemid 46224175)
9. Peate M., et al. (2009) The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat 116(2):215-223
10. Peate M., et al. (2011) Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer. Breast J 17(1):112-114
11. Oktay K, Buyuk E (2004) Fertility preservation in women undergoing cancer treatment. Lancet 363(9423):1830
12. Oktay K., et al. (2010) In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 20(5):634-638
13. Oktay K., et al. (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347-4353 (Pubitemid 46207008)
14. Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26(16):2630-2635
15. Huang JY., et al. (2010) Retrieval of immature oocytes from unstimulated ovaries followed by in vitro maturation and vitrification: A novel strategy of fertility preservation for breast cancer patients. Am J Surg 200(1):177-183
16. Hulvat MC, Jeruss JS (2009) Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol 10(5-6):308-317
17. Porcu E., et al. (2008) Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diab Obes 15(6):529-535
18. Sanchez-Serrano M., et al. (2010) Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril 93(1):268 e11-e13
19. Partridge AH, Ruddy KJ (2007) Fertility and adjuvant treatment in young women with breast cancer. Breast 2(16 Suppl):S175-S181
20. Madrigrano A, Westphal L, Wapnir I (2007) Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg 194(4):477-481 (Pubitemid 47361049)
21. Giuseppe L., et al. (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12(2):141-147 (Pubitemid 46605523)
22. Badawy A., et al. (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapyinduced ovarian damage: prospective randomized study. Fertil Steril 91(3):694-697
23. Recchia F., et al. (2006) Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106(3):514-523 (Pubitemid 43157613)
24. Urruticoechea A., et al. (2008) Ovarian protection with goserelin during adjuvant chemotherapy for premenopausal women with early breast cancer (EBC). Breast Cancer Res Treat 110(3):411-416 (Pubitemid 351962592)
25. Blumenfeld Z, Eckman A (2005) Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 34:40-43
26. Sverrisdottir A., et al. (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117(3):561-567
27. Ismail-Khan R., et al. (2008) Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. In American Society of clinical oncology annual meeting, Chicago, IL
28. Gerber B., et al. (2009) ZORO: a prospective randomized multicenter study to prevent chemotherapyinduced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). In 2009 ASCO annual meeting
29. Southwest Oncology Group: The Group Newsletter (2008) [cited; Volume 22, No. 1: [Available from: http://www.swog.org/Visitors/Download/ Newsletters/Newsletter022008.pdf
30. Partridge A., et al. (2007) Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 43(11):1646-1653 (Pubitemid 47042368)
31. Fornier MN., et al. (2005) Incidence of chemotherapyinduced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104(8): 1575-1579 (Pubitemid 41437419)
32. Koyama H., et al. (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39(4):1403-1409 (Pubitemid 8108291)
33. Minton SE, Munster PN (2002) Chemotherapyinduced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9(6):466-472 (Pubitemid 35462551)
34. Parulekar WR., et al. (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5.. J Clin Oncol 23(25):6002-6008
35. Ruddy KJ, Partridge AH (2009) Fertility. In: Castiglione M, Piccart MJ (eds) Adjuvant therapy for breast cancer. Springer, The Netherlands, pp 367-385
36. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14(5):1718-1729 (Pubitemid 26134232)
37. Goldhirsch A, Gelber RD, Castiglione M (1990) The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1(3):183-188 (Pubitemid 20218533)
38. Petrek JA., et al. (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24(7):1045-1051 (Pubitemid 46638800)
39. Abusief ME., et al. (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116(4):791-798
40. Sukumvanich P., et al. (2010) Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 116(13):3102-3111
41. Tham YL., et al. (2007) The rates of chemotherapyinduced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30(2):126-132
42. Najafi S., et al. (2011) Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. Menopause 18(2):208-212
43. Anderson RA., et al. (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583-2592 (Pubitemid 44542149)
44. Zhou WB., et al. (2010) Incidence of chemotherapyinduced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer 10:281
45. La Marca A., et al. (2010) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16(2):113-130
46. Lutchman Singh K., et al. (2007) Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96(12):1808-1816 (Pubitemid 46912025)
47. Su HI., et al. (2010) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3):592-599
48. Anders C., et al. (2008) A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26(3):286-295 (Pubitemid 351329008)
49. Partridge AH., et al. (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94(2):634-644
50. Yu B., et al. (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099-2105
51. Fox KR, Scialla J, Moore H (2003) Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer [abstract 50]. Proc Am Soc Clin Onc 22:13
52. Ives A., et al. (2007) Pregnancy after breast cancer: population based study. BMJ 334(7586):194
53. Hawkins MM (1994) Pregnancy outcome and offspring after childhood cancer. BMJ 309(6961):1034
54. Blakely LJ., et al. (2004) Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100(3):465-469 (Pubitemid 38124762)
55. Velentgas P., et al. (1999) Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 85(11):2424-2432 (Pubitemid 29244851)
56. Mulvihill JJ., et al. (1987) Pregnancy outcome in cancer patients. Experience in a large cooperative group. Cancer 60(5):1143-1150 (Pubitemid 17157234)
57. Dow KH, Harris JR, Roy C (1994) Pregnancy after breast-conserving surgery and radiation therapy for breast cancer. J Natl Cancer Inst Monogr 16:131-137
58. Sankila R, Heinavaara S, Hakulinen T (1994) Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". Am J Obstet Gynecol 170(3):818-823 (Pubitemid 24224706)
59. Kroman N., et al. (1997) Time since childbirth and prognosis in primary breast cancer: population based study. BMJ 315(7112):851-855 (Pubitemid 27420444)
60. von Schoultz E., et al. (1995) Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 13(2):430-434
61. Kranick JA., et al. (2010) Is pregnancy after breast cancer safe? Breast J 16(4):404-411
62. Rippy EE, Karat IF, Kissin MW (2009) Pregnancy after breast cancer: the importance of active counselling and planning. Breast 18(6):345-350
63. Swain SM., et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362(22):2053-2065
64. Ellis M (2010) Taxane-based chemotherapy for nodepositive breast cancer-take-home lessons. N Engl J Med 362(22):2122-2124
65. Puhalla S, Brufsky A, Davidson N (2009) Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast 18(Suppl 3):S122-S1230
66. Lee SJ., et al. (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24(18):2917-2931 (Pubitemid 46655598)
67. Goodwin PJ., et al. (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365-2370 (Pubitemid 29368234)
68. Burstein HJ, Winer EP (2000) Primary care for survivors of breast cancer. N Engl J Med 343(15):1086-1094
69. Martin M., et al. (2005) Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 352(22):2302-2313 (Pubitemid 40740554)
70. Han HS., et al. (2008) Analysis of chemotherapyinduced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115(2):335-342
71. Reh A, Oktem O, Oktay K (2008) Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 90(5):1635-1639
72. Swain SM., et al. (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113(2):315-320
73. Levine MN., et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16(8):2651-2658 (Pubitemid 28363028)
74. Venturini M., et al. (2005) Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97(23):1724-1733 (Pubitemid 41782282)
75. Berliere M., et al. (2008) Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8:56